Lillian L. Siu, MD, FAACR

Lillian L. Siu, MD, FAACR

Director, Phase I Clinical Trials Program
Codirector, Robert and Maggie Bras and Family Drug Development Program
Clinical Lead, Tumor Immunotherapy Program
BMO Chair, Precision Cancer Genomics
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Dr. Siu is a senior medical oncologist, director of the Phase I Clinical Trials Program, codirector of the Robert and Maggie Bras and Family Drug Development Program, clinical lead for the Tumor Immunotherapy Program, and the BMO Chair in Precision Cancer Genomics at the Princess Margaret Cancer Centre, University Health Network in Toronto, Canada. She is also a professor of medicine at the University of Toronto. Throughout her career, Siu has made crucial contributions to anticancer drug development and translational and clinical research. Her innovative research dedicated to optimizing clinical trial design and execution has resulted in the accelerated discovery and development of novel immunotherapeutics and molecularly targeted therapeutics for patients with head and neck cancers as well as gastrointestinal malignancies.

Siu has been a member of the AACR since 1996 and was recently elected as a Fellow of the AACR Academy. She has greatly contributed to the growth of the AACR through her leadership and involvement with numerous AACR committees and association groups. She is a member of the AACR International-Canada Board of Directors (2020-present) and AACR Finance and Audit Committee (2019-present) and a former member of the AACR Board of Directors (2017-2020). Siu has been invaluable in shaping AACR Annual Meetings by serving as a cochair (2016, 2012) and member (2014) of the Annual Meeting Program Committee; cochair (2016-2017) and member (2014-2016, 2012-2013) of the Annual Meeting Clinical Trials Committee; and chair (2012) and member (2011) of the Annual Meeting Education Committee. She will serve as a chair of the 2025 Annual Meeting Program Committee. She has also expertly contributed to other AACR meetings, special conferences, and workshops by serving as scientific committee cochair of the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium (2021-2022); cochair of the AACR Special Conference in Cancer Research: Advancing Precision Medicine Drug Development (2020); and cochair (2008-2010) and faculty member (2003-2007, 1998) of the AACR/ASCO Methods in Clinical Cancer Research Workshop.

Siu has provided important guidance as a member of the AACR Asian/Asian American Task Force (2023-present); Clinical Trials Advisory Council (2023-present); International Affairs Committee (2018-2020); Regional Advisory Committee on Canada (2016-2019); SU2C/AACR Catalyst™ Initiative Grants Executive Committee (2016); Women in Cancer Research Council (2013-2016); Clinical and Translational Cancer Research Grants Committee (2010); Henry Shepard Bladder Cancer Research Grants Scientific Review Committee (2009); and International Membership Committee (2002-2003). She has supported the AACR’s Scientific Achievement Awards Program by serving as a member of the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research Committee (2017-2019); member of the Nominating Committee (2014-2016); chair of the Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research Committee (2012-2014); and member of the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship Committee (2008).

In addition, Siu has supported the AACR’s journals by serving as editor-in-chief of Cancer Research Communications (2021-present); member of the Publications Committee (2016-present); and scientific editor of Cancer Discovery (2011-2021).

Siu has been recognized with numerous awards throughout her career, including the Canadian Cancer Trials Group Maria Ricci Lectureship (2023); the American Society of Clinical Oncology International Women Who Conquer Cancer Mentorship Award (2020); the European Society for Medical Oncology Targeted Anticancer Therapies Honorary Award (2020); the University of Toronto Michael Hutcheon Mentor Award (2017), Eaton Research Scholar Researcher of the Year (2016), and Elsie Winifred Crann Memorial Trust Award in Medical Research (2001); and the National Cancer Institute Michaele C. Christian Oncology Development Lectureship and Award (2010). Siu is an elected fellow of the Canadian Academy of Health Sciences (2023) and the American Society of Clinical Oncology (2015).

Siu received her medical degree at the University of Toronto. She completed the Canadian Association of Medical Oncology Fellowship in Oncopharmacology at the Princess Margaret Cancer Centre and a clinical research fellowship in new drug development at the University of Texas Health Science Center at San Antonio.